martes, 19 de marzo de 2013

Pharma & Interpol: Alianza estratégica...


LYON, France – Combating the global scourge of fake medicines which threatens the health of millions of people is the focus of a landmark agreement between INTERPOL and 29 of the world’s largest pharmaceutical companies. 

 The three-year deal, worth EUR 4.5 million, will see the creation of INTERPOL’s Pharmaceutical Crime Programme to further build on the work of its Medical Product Counterfeiting and Pharmaceutical Crime (MPCPC) unit. This will enhance the law enforcement community’s response to pharmaceutical crime through stronger partnership development. 

 The programme will focus on the prevention of all types of pharmaceutical crime including branded and generic drug counterfeiting as well as the identification and dismantling of organized crime networks linked to this illegal activity, which generates millions in illicit profits every year. 

 “With no country, no drug, no medical product immune from counterfeiting, a global effort is needed to combat this threat which puts the lives of millions of people at risk every single day,” said INTERPOL Secretary General Ronald K. Noble. 

 “This support from a group of 29 companies from the pharmaceutical industry forms a bridge between the public and private sectors and will assist INTERPOL and each of its 190 member countries to more effectively tackle the problem of medical product counterfeiting,” added the INTERPOL Chief. 

.../...

Both brand-name and generic pharmaceuticals are susceptible to counterfeiting, putting patient lives at risk,” said Haruo Naito, President and CEO of Eisai. 

Más
Publicar un comentario